Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic factors for response to chemotherapy containing platinum derivatives in patients with unresectable non-small cell lung cancer. (NSCLC).
Borges M, Sculier JP, Paesmans M, Richez M, Bureau G, Dabouis G, Lecomte J, Michel J, Van Cutsem O, Schmerber J, Giner V, Berchier MC, Sergysels R, Mommen P, Klastersky J. Borges M, et al. Among authors: van cutsem o. Lung Cancer. 1996 Dec;16(1):21-33. doi: 10.1016/s0169-5002(96)00609-5. Lung Cancer. 1996. PMID: 9017582
A phase III randomised study comparing concomitant radiochemotherapy with cisplatin and docetaxel as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer.
Sculier JP, Lafitte JJ, Berghmans T, Meert AP, Scherpereel A, Roelandts M, Van Cutsem O, Colinet B, Bonduelle Y, Giner V, Paesmans M, Leclercq N, Van Houtte P. Sculier JP, et al. Among authors: van cutsem o. Lung Cancer. 2018 Mar;117:32-37. doi: 10.1016/j.lungcan.2017.12.016. Epub 2018 Jan 31. Lung Cancer. 2018. PMID: 29496253 Clinical Trial.
A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5 fluorouracile: a regimen associated with major toxicity in patients with advanced non-small cell lung cancer.
Klastersky J, Sculier JP, Ries F, Dabouis G, Libert P, Schmerber J, Thiriaux J, Berchier MC, Bureau G, Van Cutsem O, et al. Klastersky J, et al. Among authors: van cutsem o. Lung Cancer. 1994 Dec;11(5-6):373-84. doi: 10.1016/0169-5002(94)92166-0. Lung Cancer. 1994. PMID: 7704494 Clinical Trial.
Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party.
Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, Michel J, Van Cutsem O, Sergysels R, Mommen P, et al. Paesmans M, et al. Among authors: van cutsem o. J Clin Oncol. 1995 May;13(5):1221-30. doi: 10.1200/JCO.1995.13.5.1221. J Clin Oncol. 1995. PMID: 7738625 Clinical Trial.
Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party.
Sculier JP, Paesmans M, Bureau G, Dabouis G, Libert P, Vandermoten G, Van Cutsem O, Berchier MC, Ries F, Michel J, et al. Sculier JP, et al. Among authors: van cutsem o. J Clin Oncol. 1993 Oct;11(10):1858-65. doi: 10.1200/JCO.1993.11.10.1858. J Clin Oncol. 1993. PMID: 8410110 Clinical Trial.
Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party.
Sculier JP, Paesmans M, Bureau G, Giner V, Lecomte J, Michel J, Berchier MC, Van Cutsem O, Küstner U, Kroll F, Sergysels R, Mommen P, Klastersky J. Sculier JP, et al. Among authors: van cutsem o. J Clin Oncol. 1996 Aug;14(8):2337-44. doi: 10.1200/JCO.1996.14.8.2337. J Clin Oncol. 1996. PMID: 8708726 Clinical Trial.
31 results